Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.

Jena D French Bryan R Haugen Francis P Worden Daniel W Bowles Andrew G Gianoukakis Bhavana Konda Ramona Dadu Eric J Sherman Shaylene McCue Nathan R Foster Yuri E Nikiforov Ticiana Della Justina Farias Paul J Norman Lori J Wirth

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Combination lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-naïve patients. Furthermore, the addition of pembrolizumab may be a viable salvage therapy for patients who have progressed on lenvatinib.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
advanced non small cell lung cancer
multiple sclerosis
clinical trial
open label